This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Villani, P.
Right arrow Articles by Carosi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Villani, P.
Right arrow Articles by Carosi, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2001, p. 2160-2162, Vol. 45, No. 7
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.7.2160-2162.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Pharmacokinetic Evaluation of Oral Levofloxacin in Human Immunodeficiency Virus-Infected Subjects Receiving Concomitant Antiretroviral Therapy

P. Villani,1 P. Viale,2 L. Signorini,2 B. Cadeo,2 F. Marchetti,3 A. Villani,1 C. Fiocchi,1 M. B. Regazzi,1,* and G. Carosi2

Department of Pharmacology, IRCCS Policlinico S. Matteo, Pavia,1 Clinic of Infectious Diseases, University of Brescia, Brescia,2 and Healthcare and Clinical Research, Glaxo Wellcome, Verona,3 Italy

Received 14 September 2000/Returned for modification 23 February 2001/Accepted 30 March 2001

The purpose of this study was to evaluate the pharmacokinetics (PK) profile of oral levofloxacin in human immunodeficiency virus-positive patients in steady-state treatment with nelfinavir (NFV) or with efavirenz (EFV) and to determine the effects of levofloxacin on the PK parameters of these two antiretroviral agents. For levofloxacin, plasma samples were obtained at steady state during a 24-h dosing interval. Plasma NFV and EFV concentrations were evaluated before and after 4 days of levofloxacin treatment. Levofloxacin PK do not seem affected by NFV and EFV. There was no significant difference between NFV and EFV plasma levels obtained with and without levofloxacin.

* Corresponding author. Mailing address: Department of Pharmacology, Laboratory of Clinical Pharmacokinetics, IRCCS, Policlinico S. Matteo, P. le Golgi 2, 27100 Pavia, Italy. Phone: 39 382 503471. Fax: 39 382 422701. E-mail: regazzim{at}smatteo.pv.it.

Antimicrobial Agents and Chemotherapy, July 2001, p. 2160-2162, Vol. 45, No. 7
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.7.2160-2162.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.




Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»